26th week of 2011 patent applcation highlights part 57 |
Patent application number | Title | Published |
20110160156 | Pharmaceutical Composition for the Eradication of Helicobacter Pylori and Preparation Method Thereof - The present invention relates to a pharmaceutical composition and its preparation method for the eradication of | 2011-06-30 |
20110160157 | METHODS OF TREATING AN INFLAMMATORY-RELATED DISEASE - The invention relates to pharmaceutical compositions and methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA in an amount less than sufficient to inhibit CDKs. | 2011-06-30 |
20110160158 | METHODS OF TREATMENT OF BIPOLAR DISORDER - A method of treating an individual diagnosed with bipolar disorder, comprises determining the number of manic episodes and/or depressive episodes experienced by an individual exhibiting one or more symptoms of bipolar disorder (e.g., bipolar disorder I); and if the number of manic episodes and/or the number of depressive episodes is each 2 or greater (e.g., 3 or greater, 4 or greater, 5 or greater, 6 or greater, 10 or greater, or 15 or greater), administering to the individual an effective amount of a uridine composition. | 2011-06-30 |
20110160159 | TREATMENT OF CANCER - Provided are methods relating to compositions that include a CDP-topoisomerase inhibitor, e.g., a CDP-camptothecin or camptothecin derivative conjugate, e.g., CRLX101. | 2011-06-30 |
20110160160 | METHODS FOR HEAT SHOCK PROTEIN DEPENDENT CANCER TREATMENT - The present invention provides a method of treating an Hsp70 dependent cancer, including: providing at least one Hsp70 dependent cancer cell; contacting the at least one cell with a sub-effective concentration of a dihydropyrimidinone compound; and contacting the at least one cell with a sub-effective concentration of a proteasome inhibitor, wherein the sub-effective concentration of the dihydropyrimidinone compound and the sub-effective concentration of the proteasome inhibitor have a synergistic effect upon the at least one cell. | 2011-06-30 |
20110160161 | CONCENTRATED THERAPEUTIC PHOSPHOLIPID COMPOSITIONS - The invention relates to concentrated therapeutic phospholipid compositions; methods for treating or preventing diseases associated with cardiovascular disease, metabolic syndrome, inflammation and diseases associated therewith, neurodevelopmental diseases, and neurodegenerative diseases, comprising administering an effective amount of a concentrated therapeutic phospholipid composition. | 2011-06-30 |
20110160162 | PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS - Disclosed are prodrugs of A | 2011-06-30 |
20110160163 | INHIBITORS OF p38 - The present invention relates to inhibitors of p38, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to inhibitors of ZAP70. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders. | 2011-06-30 |
20110160164 | COMPOUNDS FOR NONSENSE SUPPRESSION AND METHODS FOR THEIR USE - The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a nonsense mutation in an mRNA. | 2011-06-30 |
20110160165 | 7-Pyrazolyl Tetracycline Compounds and Methods of Use Thereof - The present invention provides compounds of Formula (I) and related methods and formulations: | 2011-06-30 |
20110160166 | Therapeutic composition for the treatment and prevention of athlete's foot and fungal infections of the nail and surrounding tissues - Methods and topical pharmaceutical formulations are provided for the treatment of athlete's foot (tinea pedis) and nail fungus (onychomycosis). The invention involves an anhydrous composition containing a therapeutically effective amount of salicylic acid. Repeated applications of the resulting formula over a 4-12 week period resolve most infections without the use of systemic drugs. | 2011-06-30 |
20110160167 | Steroid Derivatives Acting As Glucocorticosteroid Receptor Agonists - The present invention provides compounds of formula (I) wherein n, p, R | 2011-06-30 |
20110160168 | MODULATION OF SOLUBILITY, STABILITY, ABSORPTION, METABOLISM, AND PHARMACOKINETIC PROFILE OF LIPOPHILIC DRUGS BY STEROLS - A formulation for drug delivery, providing enhanced modulation of solubility, stability, absorption, metabolism, and/or pharmacokinetic profile of a lipophilic therapeutic agent by formulation with sterols and/or sterol esters, resulting in higher bioavailability of a therapeutic agent administered to a subject in need of such therapeutic agent. The formulation contains a therapeutic agent and a sterol or sterol ester, and can, optionally, further contain a solubilizer and/or an enhancing agent. Also described are pharmaceutical compositions containing the formulations and methods of making and methods of using the formulations and pharmaceutical compositions. Formulations of the disclosure can be constituted to minimize the synthesis of dihydrotestosterone when the therapeutic agent includes testosterone or testosterone esters. | 2011-06-30 |
20110160169 | METHOD FOR PRODUCING HIGH SAPOGENIN CONTENT COMPOSITION - A method for producing a high sapogenin content composition, including: allowing a strong acid aqueous solution having a concentration of 0.01 mol/L to 4 mol/L to act on a saponin-containing plant, so as to perform hydrolysis treatment; neutralizing a liquid obtained by the hydrolysis treatment; filtering the liquid so as to obtain a residue; and drying the residue. | 2011-06-30 |
20110160170 | COMPOSITIONS AND METHODS OF INDUCING ENDOPLASMIC RETICULUM STRESS RESPONSE - The present invention provides methods of inducing cell cycle arrest and/or cell growth inhibition, with the methods comprising administering to the cells an effective dose of the compounds of the present invention. | 2011-06-30 |
20110160171 | TREATMENT OF CONGESTION USING STEROIDS AND ADRENERGICS - A decongestant composition is provided comprising: (a) a safe and effective amount of an adrenergic compound; (b) a safe and effective amount of a steroid; and (c) a pharmaceutically-acceptable carrier. Methods of treating congestion in a human or animal subject are also provided comprising administering to the subject a composition comprising: (a) an adrenergic compound; and (b) a steroid; where the daily dose of the adrenergic compound administered to the subject is from about 1 μg to about 800 μg, and the daily dose of the steroid administered to the subject is from about 1 μg to about 400 μg. | 2011-06-30 |
20110160172 | FLUOROQUINOLONE DERIVATIVES FOR OPHTHALMIC APPLICATIONS - The present invention relates to fluoroquinolone derivatives having enhanced ocular penetration characteristics and/or antimicrobial activity, and to compositions comprising such derivatives. The derivatives and compositions are particularly well suited for treating ophthalmic bacterial infections. The present invention more particularly relates to the discovery that a 2-methyl substitution on a diazabicyclo group attached to a fluoroquinolone ring system produces improved permeability characteristics, and that a 5-amino substitution on a fluoroquinolone ring system results in improved anti-microbial activity. | 2011-06-30 |
20110160173 | Method Of Treating Human Skin And A Skin Care Composition For Use In Such A Method - One aspect of the invention concerns a cosmetic method of treating human skin by delivering an estrogenic component to said skin. The method comprises applying to the skin a composition containing: (i) at least 5 μg/g of an estrogenic component selected from the group consisting of substances represented by the following formula (I) in which formula R | 2011-06-30 |
20110160174 | Method Of Treating Disorder Related To High Cholesterol Concentration - A method of treating a disorder related to a high cholesterol concentration, comprising administering to a subject in need thereof a compound of formula (I): | 2011-06-30 |
20110160175 | 18,21-Didesoxymacbecin Derivatives for the Treatment of Cancer - The present invention relates to macbecin analogues that are useful, e.g. in the treatment of cancer, B-cell malignancies, malaria, fungal infection, diseases of the central nervous system and neurodegenerative diseases, diseases dependent on angiogenesis, autoimmune diseases and/or as a prophylactic pre-treatment for cancer. The present invention also provides methods for the production of these compounds involving incorporation of non-natural starter units and their use in medicine, in particular in the treatment and/or prophylaxis of cancer or B-cell malignancies. | 2011-06-30 |
20110160176 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR - The invention relates to compounds of the formula (I) wherein n is 0, 1 or 2; G is CH | 2011-06-30 |
20110160177 | NOVEL CARBAPENEM DERIVATIVES - The present invention includes novel carbapenem derivatives having structural formula (I) or (II): | 2011-06-30 |
20110160178 | HETEROSUBSTITUTED N-THIOLATED BETA-LACTAM COMPOUNDS AND METHODS OF USE - The invention relates to heterosubstituted N-thiolated beta-lactams, compositions comprising these compounds, methods for their production, and methods of use as antibiotics to inhibit the growth of bacteria. In one embodiment, the compounds have the structure shown in formula (A) or formula (B) or formula (C): | 2011-06-30 |
20110160179 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES - The present invention provides novel substituted amino-azetidines that are useful as cannabinoid receptor antagonists/inverse agonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, dyslipidemias, cardiovascular disorders, hepatic disorders, and a combination thereof. | 2011-06-30 |
20110160180 | Cannabinoid Receptor Ligands - Compounds of Formulae (I), or pharmaceutically acceptable salts thereof: wherein R | 2011-06-30 |
20110160181 | SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS - The present invention relates to substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals. | 2011-06-30 |
20110160182 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS - Pyrazine compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like. | 2011-06-30 |
20110160183 | INHIBITORS OF AKT ACTIVITY - The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer. | 2011-06-30 |
20110160184 | Dibenzothiazepine Derivatives and Use Thereof - Compounds the following formula: wherein Z is as described in the specification, pharmaceutically acceptable salts thereof, compositions comprising the same, and methods of treating bipolar disorder, an anxiety disorder, a mood disorder or schizophrenia or other psychotic disorder with said compounds. | 2011-06-30 |
20110160185 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS - Pyrrolopyrimidine derivatives of Formula (I) that are useful as JAK3 kinase inhibitors. | 2011-06-30 |
20110160186 | Methods of Treating CYP2D6 Alternative Metabolizers - The invention provides various methods comprising the administration of a CYP2D6 bioactive drug covalently bound to a water-soluble oligomer. Metabolism of CYP2D6 bioactive drug conjugates is diverted from CYP2D6 to alternative pathways, and the conjugates may therefore be utilized to alleviate the problems associated with interpopulation variation resulting from the genetic polymorphism in the CYP2D6 gene. | 2011-06-30 |
20110160187 | 3-aryl-5,6-disubstituted pyridazines - The present invention provides compounds of Formula (I) or (II) salt form or prodrug thereof, wherein variables are defined herein, that are modulators of metalloproteases such as matrix metalloproteases (MMPs) and ADAMs. The compounds or compositions described herein can be used to treat diseases associated with metalloprotease activity including, for example, arthritis, cancer, cardiovascular disorders, skin disorders, inflammation or allergic conditions. | 2011-06-30 |
20110160188 | PARAMYXOVIRUS FAMILY INHIBITORS AND METHODS OF USE THEREOF - Embodiments of the present disclosure include methods for identifying a compound or compounds useful as therapeutic agents in the treatment of paramyxovirus infections, compounds for the treatment of measles, and high throughput screening methods for identifying compounds capable of inhibiting the proliferation of a paramyxovirus. | 2011-06-30 |
20110160189 | COMPOUND THAT CAN INHIBIT UBC13-UEV INTERACTIONS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC USES - The invention relates to a compound (I) wherein R is a heterocyclyl radical; R | 2011-06-30 |
20110160190 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS - In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of VEGF production, in the treatment of solid tumor cancer, and in reducing plasma and/or tumor VEGF levels, are provided. In another aspect of the invention, methods are provided for the inhibition of VEGF production, the treatment of cancer, and the reduction of plasma and/or tumor VEGF levels, using the compounds of the invention. | 2011-06-30 |
20110160191 | NEW FUSED POLYCYCLIC COMPOUNDS HAVING A HETEROCYCLIC RING(S) AND PHARMACEUTICAL USE THEREOF - The present invention provides a fused polycyclic compound of the following formula, analogues thereof and pharmaceutically acceptable salts thereof; and agents for increasing the sugar-transporting capacity, hypoglycemic agents and pharmaceutical compositions containing the above compounds. This fused polycyclic compound has high medicinal properties and few side-effects, and a therapeutic effect on diabetes. | 2011-06-30 |
20110160192 | BIARYL AMINO ACIDS AND THEIR USE IN DNA BINDING OLIGOMERS - Compounds of formula (I): Z′-CO-A-B—NH-Z (I) wherein: Z is H or an amino protecting group; Z′ is OH, a protected or activated hydroxyl group or Cl; A is an optionally substituted C | 2011-06-30 |
20110160193 | New Benzothiazinone Derivatives and Their Use as Antibacterial Agents - The present invention relates to novel benzothiazinone derivatives and their use as antibacterial agents in infectious diseases of mammals (humans and animals) caused by bacteria, especially diseases like tuberculosis (TB) and leprosy caused by mycobacteria. The present invention aims at the generation of new compounds with activity against mycobacteria as potential new tuberculosis drugs to overcome problems concerning resistance and drug intolerance. The solution of the present invention is a compound of formula I | 2011-06-30 |
20110160194 | Anti-Inflammatory Analgesic External Preparation - An external preparation that effectively produces the anti-inflammatory analgesic effect of a non-steroidal anti-inflammatory analgesic agent, and reduces skin irritation on the application site of the preparation and has an excellent effect on pain associated with inflammation such as chronic rheumatoid arthritis, osteoarthritis, and also lumbago is provided. The external preparation includes a non-steroidal anti-inflammatory analgesic agent and oxybuprocaine or a pharmaceutically acceptable salt thereof. The external preparation includes the non-steroidal anti-inflammatory analgesic agent at a content of 0.1 to 10 wt % based on the total weight of the formulation and oxybuprocaine or a pharmaceutically acceptable salt thereof at a content of 0.01 to 60 wt % based on the total weight of the formulation. The external preparation has a dosage form as an external preparation wherein the dosage form is an ointment, a solution, a suspension, an emulsion, a lotion, a cataplasm, a tape, an aerosol, or a powder for external use. | 2011-06-30 |
20110160195 | Arthroscopic Irrigation Solution and Method for Peripheral Vasoconstriction and Inhibition of Pain and Inflammation - A method and solution for perioperatively inhibiting a variety of pain and inflammation processes during arthroscopic procedures. The solution preferably includes a vasoconstrictor that exhibits alpha-adrenergic activity and one or more additional pain and inflammation inhibitory agents at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. The solution is applied by continuous irrigation of a wound during a surgical procedure for peripheral vasoconstriction and inhibition of pain and/or inflammation while avoiding undesirable side effects associated with systemic application of larger doses of the agents. | 2011-06-30 |
20110160196 | FACTOR XA INHIBITORS - The present invention is directed to compounds represented by Formula (I) or a pharmaceutically acceptable salt, ester, or prodrug thereof which are inhibitors of Factor Xa. The present invention is also directed to intermediates used in making such compounds, pharmaceutical compositions containing such compounds, methods to prevent or treat certain conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample. | 2011-06-30 |
20110160197 | Substituted Indoles and a Method for the Production and Use Thereof - The invention relates to novel substituted indoles, to the use thereof in the form of pharmacological composition substances and to use of said composition for producing medicinal preparations used for preventing and treating viral diseases, in particular caused by viruses of infectious hepatitis (HCV, HBV), human immune deficiency (HIV), atypical pneumonia (SARS) and bird flu. The invention proposes novel substituted indoles of general formula (1) or the racemates or the optical isomers or the pharmaceutically acceptable salts and/or hydrates thereof, wherein R | 2011-06-30 |
20110160198 | SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF - The present invention is directed to substituted azoanthracene derivatives or pharmaceutically acceptable salts thereof that modulate the human GLP-1 receptor and that may be useful in the treatment of diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial, such as diabetes mellitus type 2. The invention is also directed to pharmaceutical compositions comprising these compounds and to the use of these compounds and compositions in the treatment of such diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial. | 2011-06-30 |
20110160199 | Aralkyl Substituted Piperidine or Piperazine Derivatives and Their Use for Treating Schizophrenia - The present invention discloses an aralkyl substituted piperidine or piperazine derivative and the use of the derivative in preparation of medicaments for treating schizophrenia and correlative psychoneuroses. It is shown by pharmacological tests that the derivative of the present invention has better antischizophrenic effect and less toxicity. Said derivative is a free base or salt of the compound having the following general formula. | 2011-06-30 |
20110160200 | Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension - The invention relates to methods of treating, preventing or delaying the onset or development of pulmonary hypertension using hydroxyl donors or pharmaceutically acceptable salts thereof. The invention further relates to methods of reducing mean pulmonary arterial pressure using hydroxyl donors or pharmaceutically acceptable salts thereof. | 2011-06-30 |
20110160201 | COMPOUND WITH SEROTONINERGIC ACTIVITY, PROCESS FOR PREPARING IT AND PHARMACEUTICAL COMPOSITION COMPRISING IT - Compound of formula (I) in which R1, R2 and R3 are defined in the following description, and the pharmaceutically acceptable acid-addition or base-addition salts thereof. The invention also relates to a process and an intermediate for preparing it, and to a pharmaceutical composition comprising it. The invention also relates to the use of a novel 2H-pyrrolo[3,4-c]quinoline compound for preparing a pharmaceutical composition that is active in the treatment of disturbances of the serotoninergic system. | 2011-06-30 |
20110160202 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS - Pyrazine compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like. | 2011-06-30 |
20110160203 | Substituted Pyrrolo-Aminopyrimidine Compounds - The present invention relates to substituted pyrrolo-aminopyrimidine compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted pyrrolo-aminopyrimidine compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof. | 2011-06-30 |
20110160204 | PYRIDOPYRAZINES AND DERIVATIVES THEREOF AS ALK AND c-MET INHIBITORS - The present invention provides a compound of Formula I | 2011-06-30 |
20110160205 | NOVEL 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40 - The present invention relates to novel 1-benzyl-3-hydroxymethylindazole derivatives according to formula (I) described in the claims, and to a pharmaceutical composition comprising them, together with a pharmaceutically acceptable vehicle. In addition, the present invention relates to the use of 1-benzyl-3-hydroxymethylindazole derivatives for the preparation of a pharmaceutical composition that is active in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40, and to their use in a method for treating or preventing diseases based on the expression of MCP-1, CX3CR1 and p40. | 2011-06-30 |
20110160206 | TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS - The present invention provides a tri-substituted pyrimidine compound having an excellent PDE10 inhibitory activity. The present invention relates to a tri-substituted pyrimidine compound represented by the following formula [I | 2011-06-30 |
20110160207 | HETEROCYCLIC AMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS - A compound of Formula I | 2011-06-30 |
20110160208 | DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE - The present invention provides the compounds represented by formula (I): | 2011-06-30 |
20110160209 | SUBSTITUTED PYRIDAZINE CARBOXAMIDE COMPOUNDS AS KINASE INHIBITOR COMPOUNDS - Pyridazine derivatives have unexpected drug properties as inhibitors of protein kinases and are useful in treating disorders related to abnormal protein kinase activities such as cancer. | 2011-06-30 |
20110160210 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS - An ophthalmic pharmaceutical composition useful in the treatment of glaucoma and control of intraocular pressure comprising an effective amount of a selective modulator of ALK5 receptor activity is disclosed. Also disclosed is a method of treating glaucoma and controlling intraocular pressure comprising applying a therapeutically effective amount of a pharmaceutical composition comprising a selective modulator of ALK5 receptor activity to an affected eye of a patient. | 2011-06-30 |
20110160211 | CYCLOPENTYLACRYLAMIDE DERIVATIVE - A compound having a hypoglycemic effect is provided. The compound and a pharmaceutically acceptable salt thereof are useful for the treatment or prevention of diabetes, obesity, and the like. The compound is represented by the general formula (1): | 2011-06-30 |
20110160212 | CERTAIN DIPEPTIDYL PEPTIDASE INHIBITORS - Provided are certain dipeptidyl peptidase inhibitors, pharmaceutical compositions thereof, and methods of use therefor. | 2011-06-30 |
20110160213 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS - The present invention relates to the pharmaceutical compositions, more particularly to the pharmaceutical compositions comprising novel phosphodiesterase type 4 (PDE4) inhibitors, and their use in treating allergic and inflammatory disorders. | 2011-06-30 |
20110160214 | Compositions and methods for eye whitening - The invention provides compositions and methods for whitening of eyes. The provided compositions and methods utilize low concentrations of selective α-2 adrenergic receptor agonists. The compositions preferably include brimonidine. | 2011-06-30 |
20110160215 | Substituted Triazolo-Pyrazine Compounds - The present invention relates to substituted triazolo-pyrazine compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted triazolo-pyrazine compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof. | 2011-06-30 |
20110160216 | Thymidylate Synthase Haplotype is Associated with Tumor Recurrence in Stage II and Stage III Colon Cancer Patients - The invention provides compositions and methods for determining the likelihood of tumor recurrence following treatment with 5-FU based adjuvant therapy for Stage II or Stage III colon cancer patients. After determining if a patient is less likely to experience tumor recurrence once treated, the invention also provides methods for treating these patients. | 2011-06-30 |
20110160217 | DEUTERIUM ENRICHED ANALOGUES OF TADALAFIL AS PDE5 INHIBITORS - The present invention relates to derivatives of tadalafil, substituted with fluorine on the methylene carbon atom situated between the oxygens of the benzodioxol ring, and optionally further substituted with deuterium atoms in place of normally abundant hydrogen, and | 2011-06-30 |
20110160218 | COMPOSITIONS COMPRISING MACROCYCLIC LACTONE COMPOUNDS AND SPIRODIOXEPINOINDOLES - The present invention provides formulations which may comprise macrocyclic lactones and at least one spirodioxepinoindole derivative or a spirooxepinoindole derivative for combating parasites in birds and mammals. The invention also provides for an improved method for eradicating, controlling and preventing parasite infestation in birds and mammals. | 2011-06-30 |
20110160219 | Inhibitors of Phosphodiesterase Type 5A for Treating or Preventing Muscle Disease or the Symptoms Thereof in a Patient - Disclosed are pharmaceutical compositions and methods for treating or preventing muscle diseases or the symptoms thereof. The compositions typically include and the methods typically utilize phosphodiesterase type 5A inhibitors. | 2011-06-30 |
20110160220 | CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDA- ZIN-3-AMINE - The present disclosure generally relates to a crystalline form of 6-[(4S)-2-methyl-4-(naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine. The present disclosure also generally relates to pharmaceutical compositions comprising the crystalline form, as well of methods of using a crystalline form in the treatment of depression and other conditions and methods for obtaining such crystalline form. | 2011-06-30 |
20110160221 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS - The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer. | 2011-06-30 |
20110160222 | MODULATORS OF GLUCOSE HOMEOSTASIS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS - Aryl 119 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control. | 2011-06-30 |
20110160223 | NMDA Receptor Antagonists for the Treatment of Neuropsychiatric Disorders - Provided are pharmaceutical compositions and methods of treatment or prophylaxis of certain neuropsychiatric conditions, in particular mood disorders. The compounds are of the general Formula I-V as described herein. | 2011-06-30 |
20110160224 | ARIPIPRAZOLE COMPLEX FORMULATION AND METHOD - An aripiprazole formulation is provided which includes the antipsychotic agent aripiprazole in the form of an inclusion complex in a β-cyclodextrin, preferably, sulfobutyl ether β-cyclodextrin (SBECD), which in the form of an injectable produces reversible generally minimal to mild irritation at the intramuscular injection site. A method for minimizing or reducing irritation caused by aripiprazole at an intramuscular injection site and a method for treating schizophrenia employing the above formulation are also provided. | 2011-06-30 |
20110160225 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS - Disclosed herein are novel compositions and methods for treating or preventing a variety of disorders and conditions associated with lipid metabolism. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising one or more fibric acid or statin derivative compositions alone or in combination with one or more lipid altering agents and/or PDE inhibitors. | 2011-06-30 |
20110160226 | Substituted Triazolo-Pyrimidine Compounds - The present invention relates to substituted triazolo-pyrimidine compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted triazolo-pyrimidine compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof. | 2011-06-30 |
20110160227 | Prolyl Hydroxylase Inhibitors - The invention described herein relates to certain bicyclic heteroaromatic N-substituted glycine derivatives of formula (I) | 2011-06-30 |
20110160228 | DIHYDRO-ISO-CA-4 AND ANALOGUES: POTENT CYTOTOXICS, INHIBITORS OF TUBULIN POLYMERIZATION - The present invention relates to compounds of formula (I) below in which: —R | 2011-06-30 |
20110160229 | AHCY HYDROLASE INHIBITORS FOR TREATMENT OF HYPER HOMOCYSTEINEMIA - The present invention is directed to AHCY inhibitors of formula (I): which are useful in the treatment of diseases characterized by high homocysteine levels, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases characterized by high homocysteine levels. | 2011-06-30 |
20110160230 | Ceramic matrix for incorporating controlled release drugs, a tablet, method for obtaining the ceramic matrix and method for producing a tablet - The present invention refers to a ceramic nanosystem constructed for releasing medications in a controlled manner, in the treatment of human beings and animals presenting an organic deficiency which requires the application of said medications. The present invention further refers to the method for preparing said nanosystem, in the form of a ceramic matrix, and also to the method of incorporating a drug to said ceramic matrix, forming a tablet. | 2011-06-30 |
20110160231 | DIHYDROOROTATE DEHYDROGENASE AS ANTIFUNGAL DRUG TARGET AND QUINAZOLINONE-BASED INHIBITORS THEREOF - A method of identifying an antifungal agent which targets a DHODH protein (alias PyrE, dihydroorotate dehydrogenase, EC: 1.3.99.11) of a fungus comprising contacting a candidate substance with a fungal DHODH protein and determining whether the candidate substance binds or modulates the DHODH protein, wherein binding or modulation indicates that the candidate substance is an antifungal agent. Specific examples concern | 2011-06-30 |
20110160232 | CERTAIN CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF - Certain chemical entities that modulate PI3 kinase activity, and chemical entities, pharmaceutical compositions, and methods of treatments of diseases and conditions associated with PB kinase activity are described. | 2011-06-30 |
20110160233 | ANTI-VIRAL COMPOUNDS - Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections. | 2011-06-30 |
20110160234 | Tricyclic Compounds as Modulators of TNF-alpha Synthesis and as PDE4 Inhibitors - The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-α or by PDE4, including but not limited to rheumatoid arthritis. | 2011-06-30 |
20110160235 | TRIAZOLYL TROPANE DERIVATIVES - This invention relates to novel triazolyl tropane derivatives, their acceptable acid addition salts, solvates, hydrates and polymorphs thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by blocking or reducing the binding ability of the CCR5 receptor. | 2011-06-30 |
20110160236 | Treating Vascular Events with Statins by Inhibiting PAR-1 and PAR-4 - The present invention relates to new methods for treating and/or preventing vascular events by inhibiting G-coupled Protease Activating Receptor (PAR)-1 and/or PAR-4 with the administration of statins. In one embodiment, individuals who are at risk for vascular events, but have cholesterol levels (e.g., total cholesterol or Low Density Lipoprotein) in normal ranges, are treated with statins. | 2011-06-30 |
20110160237 | Substituted Heterocyclic Compounds - The present invention relates to substituted heterocyclic compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted heterocyclic compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof. | 2011-06-30 |
20110160238 | OCTAHYDROQUINOLIZINES FOR ANTIDIABETIC TREATMENT - This invention relates to octahydroquinolizines for pharmaceutical use with the following formula: (I), X=H, F; R=Methyl, Ethyl, nPropyl, nButyl. | 2011-06-30 |
20110160240 | POLYMORPHS AND SALTS OF A KINASE INHIBITOR - The present invention relates to novel crystalline polymorphic salt forms of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid, processes for the preparation thereof, compositions thereof and their use in methods of treatment and prevention of conditions mediated by casein kinase (CK) and/or poly(ADP-ribose)polymerase (PARD). | 2011-06-30 |
20110160241 | NEW PEPTIDOMIMETIC COMPOUNDS - The present invention relates to new compounds of the formula (I), (II), or (III) wherein R | 2011-06-30 |
20110160242 | Purified Pyrroloquinolinyl-Pyrrolidine-2,5-Dione Compositions And Methods For Preparing And Using Same - The present invention relates to a form 1 and form 2 polymorph of (−)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin- | 2011-06-30 |
20110160243 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS - The present invention relates to certain substituted tricyclic acid derivatives of Formula (I) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1-associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, myocardial ischemia-reperfusion injury, hypertensive nephropathy, glomerulosclerosis, gastritis, polymyositis, thyroiditis, vitiligo, hepatitis, biliary cirrhosis, microbial infections and associated diseases, viral infections and associated diseases, diseases and disorders mediated by lymphocytes, auto immune diseases, inflammatory diseases, and cancer. | 2011-06-30 |
20110160245 | COMPOSITIONS AND METHODS FOR TREATMENT OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT/HYPERACTIVITY DISORDER WITH METHYLPHENIDATE - The invention relates to a method of treating Attention Deficit Disorder (ADD) and Attention Deficit/Hyperactivity Disorder (ADHD) and compositions for topical application of methylphenidate comprising methylphenidate in a flexible, finite system wherein said composition comprises about 10 to 30 wt % methylphenidate, about 30 to 50 wt % acrylic adhesive, and about 30 to 50 wt % silicone adhesive and wherein said methylphenidate is delivered to a subject in need thereof such that the plasma concentration of methylphenidate increases over a period of about 6-16 hours, and more preferably over a period of about 6-12 hours followed by a steady decrease in plasma concentration of methylphenidate. | 2011-06-30 |
20110160246 | Neurodegenerative Protein Aggregation Inhibition Methods and Compounds - Methods and compositions are provided for reducing aggregation of neurodegenerative proteins associated with neurotoxicity or other proteins. The compounds comprise a first domain or targeting element for binding to the target proteins linked to a second domain or recruiting element that binds to an aggregation inhibiting protein, e.g. a prolyl isomerase. By associating the aggregating forming proteins or neuronal cells under conditions where aggregating proteins are produced with the compound and the aggregation inhibiting protein, aggregation is reduced. The subject agents can be used in assays, investigating the etiology of the neuronal diseases and for prophylaxis and therapy. | 2011-06-30 |
20110160247 | Aralkyl alcohol piperidine derivative and the use thereof as a medicament for treating depression - The present invention relates to an aralkyl alcohol piperidine derivative and use as antidepressant thereo. The said aralkyl alcohol piperidine derivative has a triple inhibition effect on the reuptaking of 5-HT, NA and DA. The derivative may be administered to the patient in need of such treatment in the form of composition by oral administration, injection and the like. The derivative is a compound having the following general formula or its salt: | 2011-06-30 |
20110160248 | PYRAZOLE COMPOUNDS AND USES THEREOF - The invention provides a compound of formula I: | 2011-06-30 |
20110160249 | 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITOR - A pharmaceutically acceptable salt comprising 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxy-pyridin-3-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionate as the anion and a cation selected from Na | 2011-06-30 |
20110160250 | CRYSTALLINE FORMS OF A FACTOR XA INHIBITOR - The present invention provides crystalline forms of a mesylate salt of the compound 5-chloro-N-((1-(4-(2-oxopyridin-1(2H)-yl)phenyl)-1H-imidazol-4-yl)methyl)thiophene-2-carboxamide and pharmaceutical compositions and methods thereof. | 2011-06-30 |
20110160251 | ANIMAL ECTOPARASITE CONTROL COMPOSITION - The present invention provides an animal ectoparasite control composition containing an insecticidal component and an adipate, and a method of controlling an animal ectoparasite which comprises administering an effective amount of the animal ectoparasite control composition to an animal. | 2011-06-30 |
20110160252 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OR PREVENTION OF HBV INFECTION - First, the present inventors assessed the effect of the compound represented by formula (III) below on Huh-7 cells infected with HBV, and demonstrated that the compound alone had an anti-HBV effect in vitro. | 2011-06-30 |
20110160253 | DEUTERATED TIZANIDINE - This disclosure relates to novel benzothiadiazoles, their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an α | 2011-06-30 |
20110160254 | COMBINATION OF A BIS-THIAZOLIUM SALT OR A PRECURSOR THEREOF AND ARTEMISININ OR A DERIVATIVE THEREOF FOR TREATING ACUTE MALARIA - The present invention relates to a combination of antimalarial active ingredients, namely a bisthiazolium salt or a precursor thereof and artemisinin or derivatives thereof. The invention also relates to a pharmaceutical composition comprising such a combination and use thereof in the treatment and/or prevention of malaria. | 2011-06-30 |
20110160255 | INHIBITORS OF AKT ACTIVITY - Invented are novel hetero-pyrrole compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis. | 2011-06-30 |
20110160256 | INHIBITORS OF AKT ACTIVITY - Invented are novel hetero-pyrrole compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis. | 2011-06-30 |
20110160257 | NOVEL SALTS AND POLYMORPHS OF DESAZADESFERROTHIOCIN POLYETHER ANALOGUES AS METAL CHELATION AGENTS - Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity. | 2011-06-30 |